NDA 208573 · Abbvie
Venclexta
Venetoclax · Oral · BCL-2 Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: May 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Apr 11, 2016
Approved uses
12
Original approval plus efficacy supplements
Registered trials
804
95 Phase 3, 286 recruiting
FAERS reports
62,878
56,926 serious, 17,658 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 20, 2026.
VENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.1 ) In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 1.2 Acute Myeloid Leukemia VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Mechanism: Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL and AML cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 20, 2026 Supplement 32 · Efficacy OrphanLabelMedication GuideLetter
- Feb 19, 2026 Supplement 31 · Efficacy OrphanLetterLabel
- Oct 4, 2021 Supplement 24 · Efficacy OrphanLabelLetter
- Oct 16, 2020 Supplement 20 · Efficacy · priority review OrphanLabelLetterReview
- Oct 16, 2020 Supplement 21 · Efficacy · priority review OrphanLabelLetterReview
- May 15, 2019 Supplement 13 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Nov 21, 2018 Supplement 9 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Sep 7, 2018 Supplement 7 · Efficacy · priority review OrphanLabelLetter
- Jun 8, 2018 Supplement 4 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Jun 8, 2018 Supplement 5 · Efficacy · priority review OrphanLabelLetter
- Dec 20, 2017 Supplement 3 · Efficacy · priority review OrphanLabel
- Apr 11, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanReviewLabelSummary Review
3 products under this application
- VENCLEXTA · VENETOCLAX 100MG · TABLET, ORAL · Prescription · TE AB
- VENCLEXTA · VENETOCLAX 10MG · TABLET, ORAL · Prescription · TE AB
- VENCLEXTA · VENETOCLAX 50MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Venetoclax" as an intervention, any sponsor and status, largest first.
University Hospital, AngersGovernment (non-federal)
NCT02416388 · 3,100 participants (planned) · Start Jan 2015 · Primary completion Jul 30, 2025
Drug: Idarubicin; Daunorubicin and 8 more · For: Acute Myeloid Leukemia (AML)
Sites: Amiens, France; Angers, France; Argenteuil, France · 56 sites in all
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolPivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT06764238 · 1,800 participants (planned) · Start Jan 3, 2025 · Primary completion Dec 31, 2029
Drug: Blinatumomab (Group A); Venetoclax (nonRand Group) and 1 more · For: Acute Lymphoblastic Leukemia ALL; Childhood Leukemia, Acute Lymphoblastic; B Cell Acute Lymphoblastic Leukemia (B-ALL)
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 27 sites in all
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPivotal-lookingRecruiting
Kura Oncology, Inc.Industry
NCT07007312 · 1,300 participants (planned) · Start Sep 26, 2025 · Primary completion Nov 2031
Drug: Ziftomenib; Placebo and 4 more · For: Acute Myeloid Leukemia (AML)
Sites: Gilbert, Arizona; Clovis, California; La Jolla, California · 141 sites in all
- Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML)Pivotal-lookingNot yet recruiting
University Hospital, ToulouseAcademic, hospital or other
NCT07948122 · 1,290 participants (planned) · Start Jan 4, 2027 · Primary completion Dec 31, 2035
Drug: Quizartinib; Midostaurin and 2 more · For: Acute Myeloid Leukemia
Sites: Amiens, France; Angers, France; Argenteuil, France · 55 sites in all
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03768063 · 1,000 participants (planned) · Start Feb 28, 2019 · Primary completion Jul 5, 2028
Drug: Atezolizumab; Bevacizumab and 14 more · For: Cancer
Sites: Aurora, Colorado; Trumbull, Connecticut; Boston, Massachusetts · 80 sites in all
- Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLPivotal-lookingActive, not recruiting
Acerta Pharma BVAstraZeneca (AZN)
NCT03836261 · 984 participants · Start Feb 25, 2019 · Primary completion Apr 30, 2027
Drug: Acalabrutinib; Venetoclax and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Los Angeles, California; Redondo Beach, California; Fort Wayne, Indiana · 169 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death10,347
- off label use7,028
- neutropenia3,635
- febrile neutropenia3,178
- myelosuppression3,045
- platelet count decreased2,936
- pyrexia2,849
- pneumonia2,733
- fatigue2,723
- diarrhoea2,438
- white blood cell count decreased2,384
- thrombocytopenia2,281
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 4 |
| 2015 | 23 |
| 2016 | 691 |
| 2017 | 1,800 |
| 2018 | 3,586 |
| 2019 | 5,067 |
| 2020 | 5,631 |
| 2021 | 6,270 |
| 2022 | 11,152 |
| 2023 | 8,891 |
| 2024 | 7,506 |
| 2025 | 7,297 |
| 2026 | 4,960 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Venclexta (Venetoclax)
2024 spending
$942M
Beneficiaries
21,868
107,871 claims
Per beneficiary
$43,064
$116.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $562,138,427 |
| 2021 | $690,959,199 |
| 2022 | $757,567,013 |
| 2023 | $814,653,975 |
| 2024 | $941,720,713 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Pratz KW, Jonas BA, Pullarkat V, et al. · Am J Hematol 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD, Jonas BA, Pullarkat V, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
Brown JR, Seymour JF, Jurczak W, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
Short NJ, Daver N, Dinardo CD, et al. · J Clin Oncol 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.
Kumar A, Soumerai J, Abramson JS, et al. · Blood 2025 · Clinical Trial, Phase II, Multicenter Study
- Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Sharman JP, Munir T, Grosicki S, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.